WWW.IJRPR.COM

International Journal of Research Publication and Reviews

Journal homepage: www.ijrpr.com ISSN 2582-7421

Innovative Drug Delivery Strategies for Lisinopril: Focus on Rapid Dissolving Tablets

Mr. Govind V. Tompe [1], Dr. Shivappa N. Nagoba[2]*, Mr. Rutik B. Wadje[3]

[1,2,3]Department of Pharmaceutics, Channabasweshwar Pharmacy College (Degree), Latur, Swami Ramanand teerth Marathwada university, Nanded-431606, Maharashtra, India.

For Correspondence:
Prof. Dr. Nagoba Shivappa N.
M. Pharm, Ph.D.
Professor and Head,
Department of Pharmaceutics,
Channabasweshwar Pharmacy College (Degree),
Kava Road, Latur - 413512, Dist. Latur. (MS)
Tel: (+91)-2382-641008 (O), (+91)-2382-240008(O)
Fax: +91-2382-243855
Mobile: +919637908901
E-mail: nagobashivraj@gmail.com , nshivraj11@rediffmail.com

A B S T R A C T :

Vaginal Lisinopril, an angiotensin-converting enzyme (ACE) inhibitor, plays a critical role in managing hypertension, heart failure and post-myocardial infarction by inhibiting the conversion of angiotensin I to angiotensin II, thereby reducing blood pressure and cardiac workload. However, conventional Lisinopril tablets pose several limitations, including a notably bitter taste, poor bioavailability (~25%) due to extensive first-pass metabolism and a delayed onset of action. These drawbacks can hinder patient compliance, especially among populations with swallowing difficulties such as pediatric, geriatric and dysphagic patients. Rapid Dissolving Tablets (RDTs) offer an innovative and patient-friendly alternative by disintegrating quickly in the oral cavity without the need for water, facilitating faster absorption and onset of action. The formulation of Lisinopril RDTs involves careful selection of excipients such as superdisintegrants (e.g., sodium starch glycolate, croscarmellose sodium), taste-masking agents (e.g., sweeteners, flavoring agents and ion-exchange resins), and binders that ensure mechanical strength without compromising disintegration time. Optimization techniques like direct compression, sublimation, lyophilization and 3D printing have been explored to enhance tablet performance. Evaluation parameters critical for RDTs include disintegration time, wetting time, mechanical strength, drug content uniformity, in vitro dissolution and palatability testing. Recent advancements have focused on nanotechnology-based carriers and polymeric films to further improve drug release and taste masking. Future research is directed toward integrating patient-centric design with scalable manufacturing technologies, ensuring both efficacy and accessibility. In conclusion, Lisinopril RDTs hold significant promise in improving therapeutic outcomes and adherence through enhanced bioavailability, palatability and ease of administration, especially for vulnerable patient groups.

Keywords: lyophilization, therapeutic outcomes, bioavailability, angiotensin-converting enzyme.

Introduction

The Lisinopril is a widely used angiotensin-converting enzyme (ACE) inhibitor prescribed for controlling high blood pressure, managing heart failure and supporting recovery after myocardial infarction. Despite its effectiveness, the conventional tablet form of Lisinopril has several drawbacks that can limit its therapeutic performance. These include an intensely bitter taste, the necessity of water for swallowing and a relatively slow onset of action due to delayed disintegration and dissolution in the gastrointestinal tract. Additionally, its oral bioavailability is limited to about 25% primarily because of significant first-pass metabolism, which reduces the amount of active drug reaching systemic circulation.[1-3]

To address these limitations, Rapid Dissolving Tablets (RDTs) have gained considerable attention. These tablets are designed to dissolve quickly in the mouth without the need for water, making them especially suitable for populations with swallowing difficulties, such as the elderly, children and patients with dysphagia. RDTs not only improve the convenience and compliance of drug administration but may also contribute to a faster onset of action by enhancing the rate at which the drug is released and absorbed. By improving patient adherence and potentially increasing therapeutic efficacy, Lisinopril RDTs represent a valuable advancement in oral drug delivery systems. Ongoing research focuses on optimizing their formulation through appropriate excipient selection, taste-masking strategies and advanced manufacturing techniques. These efforts aim to overcome the pharmacokinetic challenges of Lisinopril and deliver more effective, patient-friendly treatment options.

Lisinopril dihydrate, with a molecular weight of 441.53 g/mol, is an ACE inhibitor used to treat hypertension, heart failure and conditions following myocardial infarction. It is highly soluble in water but practically insoluble in ethanol. The drug has an oral bioavailability of approximately 25%,

which is significantly limited by first-pass metabolism. With a half-life of around 12 hours, improving its dissolution and absorption through advanced formulation strategies is essential to enhance therapeutic outcomes.

Rationale for Rapid Dissolving Tablets

RDTs offer several advantages over conventional tablet forms:

- **Enhanced Patient Compliance:** Particularly beneficial for pediatric, geriatric and psychiatric patients who may have difficulty swallowing traditional tablets.[4]
- **Rapid Onset of Action:** Facilitates faster absorption, leading to quicker therapeutic effects.
- **Convenience:** Eliminates the need for water during administration, making them ideal for on-the-go use.
- **Improved Bioavailability:** Potential for increased drug absorption due to rapid disintegration and dissolution.

Formulation Strategies

1. Direct Compression Method[6-7]

The direct compression method is highly favored in the formulation of Rapid Dissolving Tablets (RDTs) due to its straightforward procedure, cost-effectiveness and compatibility with large-scale manufacturing. This technique involves blending the active drug with carefully selected excipients and compressing the mixture directly into tablets without a prior granulation step. One of the critical components in this method is the use of superdisintegrants, such as crospovidone, sodium starch glycolate (SSG) and croscarmellose sodium. These excipients are known for their excellent water absorption and swelling properties, which cause the tablet to rapidly disintegrate upon contact with saliva, thereby enhancing dissolution and onset of action. Alongside superdisintegrants, diluents like mannitol and microcrystalline cellulose (MCC) are incorporated to provide bulk and improve mouth feel, making the tablet more palatable an essential factor in patient compliance. Binders such as poly-vinyl-pyrrolidone (PVP) and hydroxypropyl methylcellulose (HPMC) ensure that the tablet maintains its physical integrity during handling and transportation while still allowing for quick disintegration once administered. Additionally, lubricants like magnesium stearate and talc reduce friction during tablet compression and ejection from the die, ensuring smooth manufacturing without compromising tablet quality.

Formulations employing a combination of superdisintegrants have demonstrated superior performance compared to those using a single agent. For instance, a study incorporating 10% crospovidone and 5% croscarmellose sodium achieved a rapid disintegration time of approximately 145 seconds and nearly complete drug release (99%) within 30 minutes. This illustrates how optimizing excipient combinations can balance mechanical strength with rapid disintegration and dissolution, making direct compression an effective method for producing Lisinopril RDTs.

2. Freeze Drying (Lyophilization)[8]

Freeze drying or lyophilization, is a specialized technique employed to produce rapidly dissolving tablets with highly porous and lightweight structures. The process begins by dissolving or suspending the drug and excipients in a solvent system, which is then frozen at extremely low temperatures. Subsequently, the frozen matrix undergoes sublimation, where ice crystals directly convert into vapor under vacuum conditions, leaving behind a porous solid structure. This high porosity increases the surface area exposed to saliva, allowing for almost instantaneous tablet disintegration and drug dissolution upon administration. Despite its advantages in producing tablets with superior dissolution profiles and excellent mouthfeel, lyophilization has some significant limitations. The process is technically complex and requires expensive equipment and controlled conditions, leading to higher production costs. Furthermore, lyophilized tablets tend to be fragile and have lower mechanical strength, which may complicate packaging, storage and transportation. Due to these challenges, lyophilization is often reserved for drugs where rapid action is critical and cost considerations are secondary or for small-scale or specialized products.

3. Effervescent and Sublimation Techniques

Effervescent and sublimation methods are innovative strategies designed to enhance the porosity of tablets, thereby accelerating disintegration and drug release. Effervescent tablets incorporate acid-base combinations such as citric acid and sodium bicarbonate that react in the presence of saliva or moisture to release carbon dioxide gas. This gas evolution creates a bubbling effect that helps break the tablet apart quickly, improving the rate at which the active drug is available for absorption. Additionally, the effervescence can mask the unpleasant taste of drugs like Lisinopril, further improving patient acceptability.

On the other hand, the sublimation technique involves incorporating volatile substances, such as camphor or ammonium bicarbonate, into the tablet matrix. After compression, these volatile agents are removed through a drying process that causes them to evaporate or sublimate, leaving behind a porous tablet structure. The increased porosity facilitates faster penetration of saliva, which in turn leads to rapid disintegration and dissolution of the tablet. Both techniques effectively enhance the tablet's internal structure, leading to improved disintegration times and drug release rates. While these methods may add complexity to the manufacturing process, they are particularly valuable for drugs with poor water solubility or those that require rapid onset of action, such as Lisinopril.

Taste Masking Approaches

Given Lisinopril's inherent bitterness, effective taste masking is crucial:

- **Cyclodextrin Complexation:** Formation of inclusion complexes with cyclodextrins can encapsulate the drug, reducing its exposure to taste receptors.
- **Polymeric Coatings:** Coating the drug particles with polymers like Eudragit E-100 can prevent direct contact with taste buds.
- **Ion Exchange Resins:** These resins can absorb the drug, masking its taste.
- **Flavoring Agents:** Addition of sweeteners and flavoring agents can improve palatability.

Optimization technique[9-10]

Factorial Design

Factorial design is a fundamental statistical method used extensively in pharmaceutical formulation to study the simultaneous effects of two or more independent variables, known as factors, on one or more dependent variables or responses. This approach is especially valuable in early-stage formulation development because it allows researchers to understand not only the individual impact of each factor but also how they interact with one another. For example, in developing Lisinopril Rapid Dissolving Tablets (RDTs), a 3^2 factorial design may be implemented where two factors such as the concentration of a super-disintegrant and the type or amount of binder are each tested at three different levels. By conducting experiments at all possible combinations of these levels, formulators can observe how these variables influence critical tablet properties such as hardness, disintegration time and dissolution rate. This comprehensive data collection facilitates a robust understanding of the formulation space, allowing optimization of tablet performance while avoiding unnecessary trial-and-error.

Central Composite Design (CCD)

Central Composite Design (CCD) builds on the factorial design by adding center points and axial (star) points to the experimental setup, which allows for the modeling of curvature or quadratic effects in the response variables. Unlike factorial designs that typically assume linear relationships, CCD accommodates non-linear behaviors that are common in pharmaceutical formulations. For instance, increasing the concentration of a super dis-integrant in an RDT may initially improve disintegration time but could eventually weaken tablet structure if increased beyond an optimal point. CCD captures these complex interactions by including experiments that test the extremes and center of the formulation variables' range. This design aids in creating predictive models that more accurately describe the behavior of formulation factors across their entire range, making it invaluable in fine-tuning multiple parameters simultaneously. It enables formulators to identify the ideal balance between excipient concentrations to achieve the desired tablet characteristics efficiently.

Response Surface Methodology (RSM)

Response Surface Methodology (RSM) is an advanced optimization tool that uses the data generated from designs like factorial and CCD to create mathematical models describing the relationship between formulation variables and responses. By fitting a polynomial equation to the experimental data, RSM generates response surfaces and contour plots that visually represent how change in the independent variables influence the tablet's properties. This visual and quantitative approach allows formulators to explore the design space comprehensively and identify the exact combination of variables that optimize tablet performance attributes such as rapid disintegration time, sufficient hardness, and high dissolution rates. The primary advantage of RSM is its ability to minimize the number of experiments required by systematically guiding researchers toward the optimal formulation. It is widely employed in pharmaceutical development to ensure consistency, enhance quality and accelerate the product development timeline.

Evaluation Parameters[11-15]

Hardness and Friability

The mechanical strength of tablets is critical to ensure they can withstand handling, packaging, and transportation without breaking or crumbling. Hardness measures the force required to break a tablet, indicating its robustness and structural integrity. Meanwhile, friability assesses the tendency of tablets to crumble or lose weight under mechanical stress, usually by tumbling the tablets and measuring the percentage of weight loss. For Rapid Dissolving Tablets (RDTs), achieving a balance between sufficient hardness and rapid disintegration is essential; tablets must be strong enough to survive handling but still break down quickly in the oral cavity.

Weight Variation

Uniformity in tablet weight is crucial for consistent dosing, ensuring each tablet delivers the intended amount of Lisinopril. The weight variation test involves randomly selecting tablets from a batch and measuring their individual weights. Regulatory standards specify acceptable limits for weight deviation, and maintaining this uniformity confirms the manufacturing process's precision and the blend's homogeneity.

Disintegration Time

Disintegration time is a key quality attribute for RDTs, reflecting how quickly a tablet breaks down in the mouth to release the drug. Ideally, Lisinopril RDTs should disintegrate in less than 30 seconds to provide rapid onset of action and improved patient compliance. Disintegration tests simulate the oral environment, often using small volumes of fluid at body temperature, to ensure the formulation meets this fast dissolution criterion.

Dissolution Rate

The dissolution rate measures the percentage of drug released from the tablet into solution over time. It is a critical parameter that correlates with the drug's bioavailability and therapeutic effectiveness. A rapid dissolution profile is desired for Lisinopril RDTs to ensure prompt absorption and quicker clinical response. This test is typically conducted using standardized apparatus under controlled conditions to provide reproducible data on the drug release kinetics.

Taste Evaluation

Taste is a subjective but highly influential factor in patient adherence, especially for pediatric and geriatric populations. Since Lisinopril has a notably bitter taste, taste evaluation is conducted to assess the palatability of the RDT formulation. This can involve sensory panels or electronic taste sensors that evaluate the effectiveness of taste-masking agents incorporated into the formulation, aiming to improve patient acceptance and compliance.

Stability Studies

Long-term stability testing is essential to ensure that the Lisinopril RDTs maintain their physical, chemical, and microbiological quality throughout their shelf life. Tablets are stored under various environmental conditions such as different temperatures and humidity levels, and tested periodically for changes in hardness, disintegration time, drug content, and dissolution rate. Stability studies confirm that the formulation remains effective, safe, and palatable until the expiration date.

Recent Studies and Innovations

Recent advancements in RDT formulations include:

- **Nanoparticle-Based Systems:** Incorporation of nanoparticles to enhance drug solubility and absorption.
- **3D Printing:** Customization of tablet shapes and sizes to meet individual patient needs.
- **Mucoadhesive Formulations:** Development of formulations that adhere to mucosal surfaces, prolonging drug release.

Conclusion

The development of Lisinopril RDTs represents a significant advancement in pharmaceutical formulations, offering improved patient compliance and therapeutic outcomes. Through careful selection of excipients, optimization of formulation parameters and adherence to regulatory guidelines, effective RDTs can be developed. Future research should focus on exploring novel excipients, advanced manufacturing techniques and personalized medicine approaches to further enhance the efficacy and acceptability of Lisinopril therapies.

Acknowledgements

The author would like to thank Channabasweshwar Pharmacy College (Degree), Latur for providing necessary facility.

REFERENCES

1. Brahmankar DM, Jaiswal SB. (2005) Biopharmaceutics and pharmacokinetics: A treatise. Vallabhprakashan; Panigrahi, R., Chowdary, K.A., Mishra, G., Bhowmik, M., & Behera, S. (2012). Formulation of fast dissolving tablets of Lisinopril using combination of synthetic superdisintegrants. *Asian Journal of Pharmacy and Technology, 2*(3), 94-98.
2. Pazhanivel, V. (2020). Formulation and evaluation of oral disintegrating film containing Lisinopril for the effective management of hypertension and cardiac diseases. *Journal of Global Pharma Technology, 12*(11), 1-7.
3. Sameer Shafi and Nagoba Shivappa et al., (2011) "Formulation and Evaluation of Sintered Matrix Tablets of Diltiazem Hydrochloride", In International Journal of Applied Pharmaceutics.; 3(3): 294-298.
4. Alburyhi, M.M., Saif, A.A., Noman, M., & Hamidaddin, M.A. (2023). Formulation and evaluation of Lisinopril orally disintegrating tablets. *Egyptian Pharmaceutical Journal, 14*(1), 1-10.
5. Abdal-Hammid, S.N. (2013). Formulation and evaluation of Lisinopril double layer tablet. *ResearchGate*. Retrieved from https://www.researchgate.net/publication/337680606_Formulation_and_Evaluation_of_Lisinopril_Double_Layer_Tablet
6. Amipara, S. (2013). Oral disintegrating tablet of antihypertensive drug. *Journal of Drug Delivery & Therapeutics, 3*(1), 1-5.
7. Palepu S. (2019) Preparation and evaluation of fast dissolving sublingual film of lisinopril. J. Drug Delivery Ther. [Internet]. Feb. 15 [cited 2025 Jun. 15];9(1-s):101-6. Available from: https://jddtonline.info/index.php/jddt/article/view/2342
8. Moholkar Aparark V. and S. N. Nagoba, et al., (2021) "Pharmacokinetic Profile of Polyherbal Tablets Comprising Extracts of Antidiabetic Medicinal Plants," Journal of Complementary Medicine Research (JCMR).; 12(3): 01-20.
9. Jagdale SC, Suryawanshi VM, Pandya SV, Kuchekar BS, Chabukswar AR. (2014) Development of press-coated, floating-pulsatile drug delivery of lisinopril. Sci Pharm. Apr 14;82(2):423-40. doi: 10.3797/scipharm.1301-27. PMID: 24959410; PMCID: PMC4065132.
10. Panigrahi, Rajeshree, K. A. Chowdary, Gitanjali Mishra, Manas Bhowmik, & Saiprasanna Behera. (2012) "Formulation of Fast Dissolving Tablets of Lisinopril Using Combination of Synthetic Superdisintegrants." *Asian Journal of Pharmacy and Technology* [Online], 2.3; 94-98. Web. 15 Jun. 2025
11. Nagoba Shivappa N. et al., (2018) "Formulation and Evaluation of Furosemide Oral Disintegrating Tablets," In International Journal of Pharmaceutical Science Invention.; 7(6): 01-10.
12. Ijaz H, Qureshi J, Danish Z, Zaman M, Abdel-Daim M, Hanif M, Waheed I, Mohammad IS. (2015) Formulation and in-vitro evaluation of floating bilayer tablet of lisinopril maleate and metoprolol tartrate. Pak J Pharm Sci. Nov;28(6):2019-25. PMID: 26639495.
13. Vranić E, Uzunović (2008) A. Comparison of some physical parameters of whole and scored lisinopril and lisinopril/hydrochlorthiazide tablets. Bosn J Basic Med Sci. Nov;8(4):391-5. doi: 10.17305/bjbms.2008.2906. PMID: 19125715; PMCID: PMC5677287.
14. SugaveRamling V. and NagobaShivappa N. et al., (2019) "Formulation and Evaluation of fast dissolving tablets containing Amlodipine Besylate", International Journal of Bio-Pharma Research.; 8(7): 2717-2721.
15. Jagdale SC, Suryawanshi VM, Pandya SV, Kuchekar BS, Chabukswar AR. (2014) Development of press-coated, floating-pulsatile drug delivery of lisinopril. Sci Pharm. Apr 14;82(2):423-40. doi: 10.3797/scipharm.1301-27. PMID: 24959410; PMCID: PMC4065132.